Acute myeloid leukemia with t(3;21)(q26.2;q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report

KEISUKE TANAKA, GAKU OSHIKAWA, HIROKI AKIYAMA, SHINYA ISHIDA, TOSHIKAGE NAGAO, MASAHIDE YAMAMOTO and OSAMU MIURA

Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan

Received April 12, 2016; Accepted March 3, 2017

DOI: 10.3892/ol.2017.6151

Abstract. The t(3;21)(q26.2;q22) translocation is a rare chromosomal abnormality exhibited almost exclusively in therapy-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) or in the blastic crisis phase of chronic myelogenous leukemia, which results in the fusion of the runt related transcription factor 1 (RUNX1, also called AML1) gene at 21q22 to the myelodysplasia syndrome 1 (MDS1)-ecotropic virus integration site 1 (EVI1) complex locus (MECOM) at 3q26.2, generating various fusion transcripts, including AML1/MDS1/EVI1 (AME). The present study examined the case of an 84-year-old Japanese woman who developed t-MDS/AML with t(3;21)(q26.2;q22) subsequent to receiving low-dose methotrexate (MTX) treatment for rheumatoid arthritis. Following treatment with MTX for 6 years, the patient developed anemia and neutropenia, and MTX was discontinued. A total of 3 years later, the patient was diagnosed with MDS with t(3;21)(q26.2;q22) and del (5q), which progressed rapidly to AML within 3 months. The patients was subsequently treated with azacitidine and cytarabine chemotherapy, but succumbed to the disease 6 months after diagnosis. Sequencing analysis of the nested reverse transcription-PCR products from the leukemic cells revealed the expression of two types of alternatively-spliced AME transcripts with or without RUNX1 exon 6 sequences. Western blot analysis of the leukemic cells of the patient additionally revealed that the corresponding AME fusion protein products were expressed at high levels, and that these cells also prominently expressed CCAAT/enhancer-binding protein α, the repression of which has been reported to be involved in leukemogenesis mediated by AME. To the best of our knowledge, the case discussed in the present study represents the first report of MDS/AML with t(3;21)(q26.2;q22) developing following low-dose MTX therapy for rheumatoid arthritis. Nonetheless, the clinical and molecular features of the patient in the present study were representative of those patients who typically develop this disease following exposure to chemotherapy or radiotherapy for primary malignancy, which implicates MTX in the pathogenesis of t-MDS/AML. Moreover, we confirmed the expression of two AME fusion proteins for the first time in primary leukemic cells and analyzed several cellular factors implicated in AME-mediated leukemogenesis to gain some insight into its molecular mechanisms.

Introduction

A total of ~10% of acute myeloid leukemia (AML) develops following exposure to chemotherapy and/or radiation for a different primary malignancy and is categorized as therapy-related AML (t-AML) in the current World Health Organization (WHO) classification (1). The most common type of t-AML, which occurs subsequent to exposure to alkylating agents and/or radiation with a latency period of 5-10 years, is frequently preceded by therapy-related myelodysplastic syndrome (t-MDS) and is accompanied with an unbalanced loss of genetic material, often involving chromosome 5 and/or 7 (1). The less common type of t-AML, occurring following treatment with agents targeting topoisomerase II, exhibits a shorter latency period of 1-5 years without the preceding myelodysplastic phase and is often associated with balanced recurrent chromosomal translocations, frequently involving the mixed-lineage leukemia 1 (MLL) gene located at 11q23 or the runt related transcription factor 1 (RUNX1, or
alternatively designated as *AML1* gene at 21q22 (1). Although antimetabolites, including fludarabine, are also implicated in therapy-related hematological malignancies, it remains unknown if methotrexate (MTX), particularly when used at a low dose for the treatment of rheumatoid arthritis, serves a role in development of MDS/AML.

The t(3;21)(q26.2;q22) translocation is a rare chromosomal abnormality exhibited in <1% of AML/MDS, primarily t-MDS/AML or in the blastic crisis phase of chronic myelogenous leukemia (2-5). Chromosome 3q26.2 abnormalities typically activate the ecotropic virus integration site 1 (*EVI1*) gene, which has been implicated in the pathogenesis of AML and is associated with a poor prognosis (6-8). EVI1 is a nuclear transcription factor implicated in the regulation of proliferation and maintenance of hematopoietic stem cells. EVI1 also exists as the fusion protein MDS1/EVI1 (ME), which is generated by the alternative splicing of the third exon of MDS1 to the second exon of *EVI1* with the two genes located nearby to form the *MDS1-EVI1* complex locus (*MECOM*) on 3q26.2 (6,7). The most common types of 3q26.2 abnormalities are inv (3)(q21q26.2)(t;3)(q21q26.2), which define a category of AML in the WHO classification and relocate a distal enhancer of the GATA binding protein 2 (*GATA2*) gene to a region between *MDS1* and *EVI1*, which ectopically activates *EVI1* (1.7,9,10).

In contrast, t(3;21)(q26.2;q22) results in the translocation of a part of *RUNX1* at 21q22 to *MECOM* and generates various fusion transcripts (2.4). Although these fusion transcripts, including *AML1/MDS1/EVI1* (AME), have been analyzed in several cases of myeloid neoplasms associated with t(3;21)(q26.2;q22), the expression of the aberrant fusion protein products in primary leukemic cells has not previously been confirmed (3,11-16).

The present study examined a patient with MDS/A ML with t(3;21)(q26.2;q22) that developed not with exposure to chemotherapy or radiotherapy for malignancy, but following with t(3;21)(q26.2;q22) that developed not with exposure to chemotherapy or radiotherapy for malignancy, but following with t(3;21)(q26.2;q22), the expression of the aberrant fusion protein products in primary leukemic cells has not previously been confirmed (3,11-16).

The present study examined a patient with MDS/A ML with t(3;21)(q26.2;q22) that developed not with exposure to chemotherapy or radiotherapy for malignancy, but following with t(3;21)(q26.2;q22), the expression of the aberrant fusion protein products in primary leukemic cells has not previously been confirmed (3,11-16).

The present study examined a patient with MDS/A ML with t(3;21)(q26.2;q22) that developed not with exposure to chemotherapy or radiotherapy for malignancy, but following with t(3;21)(q26.2;q22), the expression of the aberrant fusion protein products in primary leukemic cells has not previously been confirmed (3,11-16).

The present study examined a patient with MDS/A ML with t(3;21)(q26.2;q22) that developed not with exposure to chemotherapy or radiotherapy for malignancy, but following with t(3;21)(q26.2;q22), the expression of the aberrant fusion protein products in primary leukemic cells has not previously been confirmed (3,11-16).

The present study examined a patient with MDS/A ML with t(3;21)(q26.2;q22) that developed not with exposure to chemotherapy or radiotherapy for malignancy, but following with t(3;21)(q26.2;q22), the expression of the aberrant fusion protein products in primary leukemic cells has not previously been confirmed (3,11-16).

The present study examined a patient with MDS/A ML with t(3;21)(q26.2;q22) that developed not with exposure to chemotherapy or radiotherapy for malignancy, but following with t(3;21)(q26.2;q22), the expression of the aberrant fusion protein products in primary leukemic cells has not previously been confirmed (3,11-16).

The present study examined a patient with MDS/A ML with t(3;21)(q26.2;q22) that developed not with exposure to chemotherapy or radiotherapy for malignancy, but following with t(3;21)(q26.2;q22), the expression of the aberrant fusion protein products in primary leukemic cells has not previously been confirmed (3,11-16).

Western blot analysis. The peripheral blood mononuclear cells from the patient and human leukemic HEL and MOLM-1 cells, obtained from the Fusaikei Cell Center (Okayama, Japan) and cultured in RPMI-1640 medium (Wako Pure Chemicals Industries, Ltd., Osaka, Japan) containing 10% fetal calf serum (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 37°C in a 5% CO₂ incubator, were lysed and subjected to western blot analysis as described previously (17). Antibodies directed against RUNX1 (catalog no., CS4336), EVI1 (catalog no., CS2593) and calreticulin (catalog no., CS12238) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Antibodies directed against CEBPα (catalog no., SC61) and heat shock protein 90 (HSP90; catalog no., SC13119) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). These first antibodies were used at 0.2 μg/ml at 4°C in overnight incubation, while the relevant secondary antibodies (HRP-linked anti-rabbit or -mouse IgG; NA934 or NA9310, respectively, from GE Healthcare Japan, Tokyo, Japan) were used at 0.2 μg/ml at room temperature for 1 h.

Case results. An 84-year-old Japanese woman was referred to the Department of Hematology of the Graduate School of Medical and Dental Sciences at Tokyo Medical and Dental University (Tokyo, Japan) in September 2013 due to anemia and the appearance of blasts in the peripheral blood. The patient had been diagnosed with rheumatoid arthritis in 1997 and subsequently treated with bucillamine from 1997 until unidentified time, actarit between August 2001 and February 2002, salazosulfapyridine between February 2002 and September 2002 and penicillamine between September 2002 and June 2005, although clinical information on the dosages of these drugs was not available. In 2004, treatment with low-dose MTX (weekly doses of 6-10 mg, adjusted by clinical and laboratory findings, divided into 2 or 3 doses orally every 12 h) and prednisolone was started. In 2006, the patient was diagnosed with lung cancer and underwent radical surgery without any chemotherapy or radiotherapy. As the patient developed anemia and neutropenia in August 2010, MTX was discontinued and substituted for tacrolimus (daily doses of 1-2 mg, adjusted by clinical and laboratory findings, orally once a day). The duration of the MTX therapy was 75 months.
and the accumulated dose was 2,204 mg. Despite stopping MTX treatment, the patient’s anemia gradually progressed, with the hemoglobin level decreasing to 6.6 g/dl (normal range, 12.0-15.0 g/dl) in September 2013, when myeloblasts and hypogranular neutrophils appeared in the peripheral blood.

On the patient's first visit to the Department of Hematology (Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University) the white blood cell count was 3.7×10^9/l (normal range, 3.6-9.3×10^9/l) with an appearance of 3% blasts, the hemoglobin level was 6.1 g/dl, and the platelet count was 155×10^9/l (normal range, 120-410×10^9/l). Bone marrow examination demonstrated slightly hypercellular marrow with 6.2% blast (normal range, 0.1-0.7%), pseudo-Pelger-Huet anomaly, hypogranular neutrophils, megaloblastoid changes, increased ringed sideroblasts (31%), and micromegakaryocytes (Fig. 1A). Flow cytometric analysis demonstrated that the blasts were positive for cluster of differentiation (CD)13 (82.2%), CD33 (43.2%, dimly expressed), and CD34 (41.7%), and partially positive for CD7 (18.5%). Cytogenetic analysis illustrated that the karyotype of the bone marrow cells was as follows: 46,XX,t(3;21)(q26.2;q22)[1]/46,idem,del(5)(q?) (16) (Fig. 1B). The position of deletion in 5q [(5)(q?)] could not be determined more precisely most likely because of the quality of metaphase samples obtained. Thus, t(3;21)(q26.2;q22) was observed in all the cells in metaphase (17) that were analyzed. In addition, the RT-PCR analysis using AML1 and EVII primers revealed two AME bands in gel electrophoresis (Fig. 2A). These RT-PCR products were isolated from the agarose gel and sequenced, which revealed two types of AME bands in gel electrophoresis, in which either exon 5 or 6 of RUNXI was directly fused with exon 2 of MECOM, as demonstrated in Fig. 2B. Consistent with this, two AME fusion proteins with apparent molecular masses of 210 and 186 kDa were detected in bone marrow mononuclear cells by western blotting with antibodies directed against EVII and RUNXI (Fig. 2C). EVII was detectable in HEL and MOLM-1 cells, but not in the patient's leukemic cells, which also expressed RUNXI, CEBPα and calreticulin at readily detectable levels.

The patient was diagnosed with MDS: Refractory anemia with excess blasts [international prognostic scoring system (IPSS) (18): Int-1; revised IPSS (19): High; WHO adapted prognostic scoring system (20): High]. Although treatment with oral metenolone acetate (15 mg/day) was started in October 2013, the patient’s anemia progressed and blasts in the peripheral blood increased. In December 2013, a bone marrow examination revealed 25.2% blasts, leading to the diagnosis of AML with myelodysplasia-related changes. In January 2014, treatment with azacitidine (75 mg/m^2/day for 7 days) was started; however, the patient's cytopenia progressed (the white blood cell count, 2.2×10^9/l; platelet count, 43×10^9/l!) and the bone marrow blasts increased. The patient was subsequently treated with low-dose cytarabine chemotherapy (10 mg/m^2/day), but succumbed to the disease in July 2014.

**Discussion**

The present study described a case of AML with t(3;21) (q26.2;q22) that developed from MDS following treatment with low-dose MTX for rheumatoid arthritis. MDS/AML with t(3;21)(q26.2;q22) has been identified almost exclusively as t-MDS/AML. For instance, a large case series examined by the University of Texas MD Anderson Cancer Center (Houston, TX, USA) revealed that 16/17 cases (94.1%) of t(3;21)(q26.2;q22) -positive MDS/AML had previously received chemotherapy or radiotherapy (5). It is well established that other balanced recurrent chromosomal translocations in t-AML, including those involving RUNXI, are typically observed following treatment with topoisoomerase II inhibitors without the antecedent MDS phase or myelodysplasia-related morphological changes, and are associated with a better prognosis compared with other types of t-AML (1). Notably, a previous study by the same group at the University of Texas MD Anderson Cancer Center implicated antimetabolites in the pathogenesis of t-MDS/AML with t(3;21)(q26.2;q22), as prior treatment with the pyrimidine analog 5-fluorouracil or the purine analog fludarabine was implicated antimetabolites in the pathogenesis of t-MDS/AML (18). However, the subsequent study revealed that a number of the...
TANAKA et al.: AML WITH t(3;21)(q26.2;q22) DEVELOPMENT FOLLOWING METHOTREXATE THERAPY

16 patients with t(3;21)(q26.2;q22)-positive t-MDS/AML also received alkylating agents and DNA topoisomerase II inhibitors for the treatment of their primary tumors (5). Thus, in contrast to t-AML associated with other balanced recurrent translocations, t-MDS/1-AML with t(3;21)(q26.2;q22) was observed subsequent to treatment with wide-ranging chemotherapeutics and demonstrated a very short overall survival rate (median, 4.7 months) (5). In the present study, the patient exhibited typical clinical and morphological features of MDS/AML associated with t(3;21)(q26.2;q22), which develops almost exclusively as t-MDS/AML (3, 5). This indicates that low-dose MTX therapy is causally associated with the development of MDS/AML, although it remains unknown whether MTX therapy for rheumatoid arthritis may serve a role in pathogenesis of MDS/AML. To the best of our knowledge, the cases of 13 patients with AML developing following low-dose MTX treatment for rheumatoid arthritis have previously been reported (Table I) (23-29). However, the clinical features, including latency periods, cumulative dosages of MTX and the presence or absence of antecedent MDS and myelodysplasia-related morphological changes have been heterogeneous among these patients. Cytogenetic changes observed in these patients have also been diverse; while complex karyotypic abnormalities were exhibited in one patient, t(8;21) was observed in two other cases (24,25,29). Conversely, the patient in the present study exhibited typical clinical and morphological features of MDS/AML associated with t(3;21)(q26.2;q22), which develops almost exclusively as t-MDS/AML (3,5). This indicates that low-dose MTX therapy is causally associated with the development of MDS/AML in the case reported in the present study, although it remains unknown whether the mechanism underlying this association involves DNA mutagenesis induced by MTX as an antimetabolite or the immunosuppressive effect of MTX. In this regard, it should be noted that rheumatoid arthritis itself has

Figure 2. Analyses of AME fusion transcripts and proteins in the leukemic cells of the patient. (A) Reverse transcription (RT) -PCR analyses of the AME fusion transcripts. M, marker lane; 1, products from RUNX1 and EVI1 primers; 2, β-actin control. Sizes are given in bp. Pt., patient’s bone marrow cells; Cont., HL60 cells; AME, AML/MDS/EVI1. The positions of longer and shorter AME (AML/MDS/EVI1) fusion transcripts, AME (L) and AME (S), as well as that of β-actin are also indicated. (B) Sequence analysis of the AME fusion transcripts obtained from RT-PCR. Arrows illustrate the boundaries of exons, with the nucleotide number for RUNX1 (NM_001001890.2) and MECOM (NM_004991.3) indicated. Vertical lines indicate the junctions of the chimeric transcripts. (C) Western blot analysis of the AME fusion proteins in patient’s leukemic cells. Total cell lysates from HEL cells, MOLM-1 cells, or patient’s bone marrow cells, as indicated, were subjected to Western blot analysis using antibodies against indicated proteins. Sizes are given in KDa. Positions of larger and smaller AME fusion proteins, AME (L) and AME (S), as well as those for EVI1, the smaller form of EVI1 lacking 324 amino acids (EVI1Δ324), and RUNX1 are also indicated. HSP90 was used for a protein loading control.
been associated with an elevated risk of AML [odds ratio (OR) 1.28, 95% confidence interval (CI) 1.11-1.47] and MDS (OR 1.52, 95% CI 1.27-1.81) (30). Additionally, rheumatoid arthritis is frequently treated with immunsuppressants in addition to MTX, as is the case for the patient in the present study who had received tacrolimus after stopping MTX. This suggests that patients with rheumatoid arthritis who are treated with MTX need to be carefully monitored for the development of MDS/AML. Further reports of patients with t-MDS/AML associated with MTX are required to clarify the etiological and clinical significance between MTX and t-MDS/AML.

The t(3;21)(q26.2;q22) translocation primarily generates the fusion gene transcript AME, although transcripts of RUNX1 fused directly with EVII or RPL22 near MECOM have also been identified (2,11,12,31). In the patient discussed in the present study, two AME fusion transcripts corresponding with RUNX1 fused at its 3' end of exon 5 or 6 to the 5' end of exon 2 of MECOM were detected. Thus, these fusion transcripts should encode the N-terminus of RUNX1 containing the DNA-binding Runt domain fused to the majority of the MDS1/EVI1 protein. These two different transcripts, presumably generated by alternative splicing, represent the two predominant forms of AME, which have previously been identified in the t(3;21)-carrying leukemic cell line SKH1 and in primary leukemic cells (3,11,16), with a few patients revealed to express both forms (14,16). However, the expression of the protein products of these fusion transcripts in primary leukemic cells has not yet been documented, to the best of our knowledge. In the present study, it was confirmed that the fusion products were expressed in present patient at a high level, comparable to that of EVII in human leukemic MOML-1 cells with inv(3)(q21.2;q26) (7,9) and HEL cells (32). The Runt domain maintained in AME is the DNA-binding domain of RUNX1, which is the DNA-binding subunit of the core-binding transcription factor that regulates the expression of genes essential for hematopoiesis. By recruiting histone deacetyltransferase and transcriptional co-repressors through the C-terminal domain of EVII, AME represses the RUNX1-dependent promoters in a dominant-negative manner, thus serving an essential role in leukemogenesis (2,4). This is consistent with the observation of the present study that the leukemic cells of the patient did not express EVII despite the fact that wild-type RUNX1 was expressed at a readily detectable level, since EVII has been suggested to be a target gene of RUNX1 (32).

AME has also been demonstrated to serve a role in leukemogenesis through the inhibition of CEBPα, a transcription factor that regulates the expression of genes associated with myeloid differentiation, including its own gene (2,4,31,33). Helbling et al (33) previously suggested that the conditional expression of AME in the myeloid leukemic cell line U937 suppressed the expression of CEBPα through the induction and activation of calreticulin, a putative inhibitor of CEBPα translation. The authors additionally demonstrated that leukemic cells from none of the 8 patients with t(3;21)-positive AML examined expressed CEBPα, although the expression of AME in these cells was not confirmed (33). By contrast, CEBPα was readily detectable in the leukemic cells from the patient in the present study. In addition, the expression of calreticulin was not distinctively enhanced in the present study, although the possible activation of calreticulin in the leukemic cells of the patient was not examined. Conversely, Tokita et al (31) revealed that AME inhibited CEBPα-mediated transcriptional activity in the murine hematopoietic progenitor cell line LG-3,
although the mRNA levels of CEBPα, a target gene of CEBPα itself, and the expression level of calreticulin was not altered by the expression of AME in these cells. These observations suggest that the effects of AME on various cellular factors and events associated with leukemogenesis may depend on the cellular context. Thus, a detailed analysis of these factors, particularly at the protein level, in primary leukemic cells is warranted to generate more data in regards to the mechanism of AME-mediated leukemogenesis.

Acknowledgements

The present study was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (grant nos. 15K09467 and 24591384).

References

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, diehl V, Stein H, Thiele J and Vardiman JW: WHO classification of tumours of haematopoietic and lymphoid tissues. Vol 2. 4th edition. IARC, 2008.
2. Nucifora G, Laricchia-Robbio L and Senyuk V: EVII and hematopoietic disorders: History and perspectives. Gene 368: 1-11, 2006.
3. Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H and Jones D: t(3;21)(q26;q22) in myeloid leukemia: An aggressive syndrome of blast transformation associated with hydroxyurea or antime-tabolite therapy. Cancer 106: 1730-1738, 2006.
4. Maki K, Yamagata T and Mitani K: Role of the RUNXI-EVI1 fusion gene in leukemogenesis. Cancer Sci 99: 1878-1883, 2008.
5. Li S, Yin CC, Medeiros LJ, Bueso-Ramos C, Lu G and Lin P: Myelodysplastic syndrome/acute myeloid leukemia with t(3;21)(q26.2;q22) is commonly a therapy-related disease associated with poor outcome. Am J Clin Pathol 138: 146-152, 2012.
6. Glass C, Wilson M, Gonzalez R, Zhang Y and Perkins AS: The role of EVII in myeloid malignancies. Blood Cell Mol Dis 53: 67-76, 2014.
7. Hiai AA and Valk PJ: Review: Aberrant EVII expression in acute myeloid leukemia. Br J Haematol 172: 870-878, 2016.
8. Morishita K, Parker DS, Macenski ML, Jenkins NA, Copeland NG and Igle HN: Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 54: 831-840, 1988.
9. Grötschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman RA, Erpelincik C, van der Velden VH, Havermans M, Avellino R, van Lot K et al: A single oncogenic enhancer rearrangement causes concomitant EVII and GATA2 deregulation in leukemia. Cell 157: 369-381, 2014.
10. Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD and Yamamoto M: A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21q26) by activating EVII expression. Cancer Cell 25: 415-427, 2014.
11. Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Han M, Yazaki Y, Ohki M and Hariri H: Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 13: 504-510, 1994.
12. Nucifora G, Begy CR, Kobayashi H, Roulston D, Claxton D, Pedersen-Bjergaard J, Parganas E, Ilhe JN and Rowley JD: Consistent intergenic splicing and production of multiple transcripts between ALMI at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci USA 91: 4004-4008, 1994.
13. Motomura S, Fujisawa S, Tsunooka S, Fujimaki K, Harano H, Mohri H, Okubo T, Fujita H, Maruta A and Kodama F: Translocation (3;21)(q26;q22) in a novo acute myelogenous leukemia. EMBO J 13: 504-510, 1994.
14. Park TS, Choi JR, Yoon SH, Song J, Kim J, Kim SJ, Kwon O and Min YH: Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNXI-MDS1-EVI1 fusion transcript. Cancer Genet Cytogenet 187: 61-73, 2008.
15. Yang JJ, Cho SY, Suh JT, Lee HJ, Lee WI, Yoon HJ, Baek SK and Park TS: Detection of RUNXI-MECOM fusion gene and t(3;21) in a very elderly patient having acute myeloid leukemia with myelodysplasia-related changes. Ann Lab Med 32: 362-365, 2012.
16. Forghieri F, Bigliardi S, Morselli P, Potenza L, Fantuzzi V, Faglioni L, Nasillo V, Messerroti A, Paolini A and Luppi M: An unusual case of splenomegaly and increased lactate dehydrogenase heralding acute myeloid leukemia with eosinophilia and RUNXI-MECOM fusion transcripts. Leuk Res Rep 3: 83-84, 2014.
17. Nogami A, Oshikawa G, Okada K, Fukutake S, Umezawa Y, Naga T, Kuros T and Miura O: FLT3-ITD confers resistance to the P3K/Akt pathway inhibitors by protecting the mTOR5/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. Oncotarget 6: 9189-9205, 2015.
18. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Valles P, Hamblin T, Osier D et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 99: 2079-2088, 1997.
19. Greenberg PL, Tuerchel H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F et al: Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120: 2454-2465, 2012.
20. Malcovati L, Porta MG, Pascale C, Invernozi R, Boni M, Travaglini E, Passamonti F, Fassan M, Cinelli G, Malifioli L, Bernasconi P et al: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 23: 7594-7603, 2005.
21. Requena F, Johansson B and Mertens FE: Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. Available at http://cgap.nci.nih.gov/Chromosomes/Mitelman. Accessed February 16, 2016.
22. Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, Kimura Y, Takeuchi M, Yosida M, Ishibashi Y et al: Methotrexate/astrogene lymphoproliferative disorders in rheumatoid arthritis: Histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91: 20-28, 2013.
23. Pointumd P, Prudat M and Peron JM: Acute leukemia after low dose methotrexate therapy in a patient with rheumatoid arthritis. J Rheumatol 20: 1215-1216, 1993.
24. Dubin Kerr L, Troy K and Isola L: Temporal association between the use of methotrexate and development of leukemia in 2 patients with rheumatoid arthritis. J Rheumatol 22: 2356-2358, 1995.
25. Rosenberg NS and Farhi DC: Myelodysplasia syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. Am J Pathol 106: 676-679, 1996.
26. Kolte B, Baer AN, Sait SN, O’Loughlin KL, Stewart CC, Barcos M, Wetzler M and Baer MR: Acute myeloid leukemia in the setting of low-dose methotrexate therapy for rheumatoid arthritis. Leuk Lymphoma 42: 371-378, 2001.
27. Choi BR, Ahn MJ, Lee WS, Kim TH, Bae SC and Jun JB: Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy. Rheumatol Int 25: 311-313, 2005.
28. Al-Anazi KA, Eltayeb KL, Bakr M and Al-Mohareb FI: Methotrexate-induced acute leukemia: Report of three cases and review of the literature. Clin Med Case Rep 2: 43-49, 2009.
29. Sakai T, Tamura S, Miyoshi T, Nunami T, Nagai K and Oshima K: Development of myeloid sarcoma after long-term methotrexate use for rheumatoid arthritis. Int J Hematol 91: 493-498, 2010.
30. Anderson LA, Pfeiffer RM, Lamdjer M, Gadalla S, Berndt SI and Engels EA: Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 100: 822-828, 2009.
31. Tokita K, Maki K and Mitani K: RUNXI/EVI1, which blocks myeloid differentiation, inhibits CCAAT-enhancer binding protein alpha function. Cancer Sci 98: 1752-1757, 2007.
32. Maicas M, Vázquez I, Vicente C, García-Sánchez MA, Marcotei N, Urquiza L, Calasanz MJ and Odero MD: Functional characterization of the promoter region of the human EVII gene in acute myeloid leukemia. RUNXI and ELK1 directly regulate its transcription. Oncogene 23: 2069-2078, 2013.
33. Helbling D, Mueller BU, Timchenko NA, Hagemeijer J, Jotterand M, Meyer -Monard S, Lister A, Rowley JD, Huegli B, Fey MFandPabi T: The leukemic fusion geneAML-MDS1-EVI1 suppresses CBP in acute myeloid leukemia by activation of Calreticulin. Proc Natl Acad Sci USA 101: 13312-13317, 2004.